Brain Death & Cerebral Circulatory Arrest
Transcranial Doppler (TCD) is a bedside, noninvasive, and repeatable tool for evaluating cerebral circulatory arrest in brain death determination. Learn how TCD supports ICU and neurocritical care teams with high diagnostic accuracy — backed by peer-reviewed research.
The Clinical Challenge
Brain death determination remains one of the most critical responsibilities in the ICU. It is defined as the irreversible loss of all brain function, including the brainstem, confirmed through clinical examination, apnea testing, and — when needed — ancillary testing. ¹ The latest 2023 AAN/AAP/CNS/SCCM consensus guideline emphasizes that ancillary testing is required when the clinical assessment cannot be safely or fully completed — such as when sedative drugs, hypothermia, or hemodynamic instability confound the exam. ¹
Transcranial Doppler (TCD) for Detecting Cerebral Circulatory Arrest
Transcranial Doppler (TCD) ultrasonography confirms brain death by detecting cerebral circulatory arrest (CCA) — the cessation of blood flow to the brain caused by rising intracranial pressure exceeding arterial perfusion pressure. TCD is uniquely suited for this role because it is: ² ³
- Bedside — performed at the patient’s ICU bed, no transport required
- Noninvasive — uses a 2 MHz pulsed-wave Doppler probe through temporal and suboccipital windows
- Repeatable — can be performed serially to track progression toward CCA
- Mildly affected by sedatives — unlike EEG, TCD evaluates blood flow rather than neuronal function, making it invaluable when barbiturates or other CNS depressants are in use ³
- Widely available — can be performed by trained intensivists or neurologists 24/7 ³
TCD Flow Patterns Indicating Cerebral Circulatory Arrest
As intracranial pressure rises and cerebral perfusion pressure falls, TCD reveals a characteristic progression of waveform changes: ³ ⁶ ⁷
Increasing pulsatility — elevated pulsatility index reflecting rising ICP; diastolic flow still present (NOT yet CCA)
Oscillating (reverberating) flow — forward systolic flow followed by reversed diastolic flow, indicating zero net forward perfusion. This occurs when ICP equals mean arterial pressure. ⁶
Systolic spikes (sharp peaks) — small, brief systolic deflections with no diastolic flow, indicating ICP approaching systolic blood pressure ⁶
Absent signal — complete disappearance of any Doppler signal over time
The World Federation of Neurology Task Force consensus established that oscillating flow and systolic spikes are the definitive Doppler patterns confirming CCA. ⁶
Examination Protocol
Based on international consensus and society guidelines, the recommended TCD protocol for CCA evaluation includes: ⁶ ⁷
- Vessels to insonate: Both middle cerebral arteries (MCAs) AND the basilar artery — CCA patterns must be present in all three ⁷
- Equipment: 2 MHz pulsed-wave Doppler probe, sample volume <10 mm ³
- Confirmation: Repeat the examination within 30 minutes to confirm findings ⁷
- Prerequisites: Patient must be hemodynamically stable (systolic BP >90–100 mmHg), normothermic (>32°C), normocapnic, and free of marked metabolic derangements ³
When TCD Is Especially Valuable
TCD serves as a critical ancillary tool in scenarios where standard clinical brain death evaluation is limited: ² ³ ⁸
- Sedative/barbiturate therapy — EEG is unreliable; TCD is mildly affected ³ ⁶
- Hypothermia protocols — confounds clinical exam
- Hemodynamic instability — apnea test cannot be safely completed ²
- Severe facial/cranial trauma — may preclude certain brainstem reflex testing
- Organ donation timelines — TCD can expedite confirmation, supporting organ procurement in optimal conditions ⁸
In a retrospective analysis of 90 patients where clinical brain death diagnosis was not feasible due to confounding factors, TCD confirmed brain death in 57% of cases. Among patients showing CCA patterns in at least one artery but not meeting full criteria, 74% were subsequently confirmed brain dead or suffered cardiovascular death — suggesting prognostic value even in incomplete exams. ⁸
Book a Live Demo
Let's Get started
Discover the future of automated Transcranial Doppler technology. Schedule a brief demo with our specialists to see how non-invasive, robotic TCD fits into your hospital’s workflow.
With real-time information, clinical teams can make more informed decisions about patient management, leading to reduced length of stay and improving patient outcomes.
With the NeuraSignal Platform, healthcare professionals can detect and manage complications more quickly, helping to prevent adverse outcomes, reduce hospital readmissions, and ultimately leading to better patient satisfaction.
References
- Greer DM et al. AAN/AAP/CNS/SCCM BD/DNC Consensus Guideline. Neurology. 2023.
- Wijdicks EFM et al. Evidence-based guideline update: Determining brain death in adults. Neurology. 2010.
- Llompart-Pou JA et al. Transcranial Sonography and CCA: A Comprehensive Review. ISRN Neurology. 2013.
- Chang JJ et al. Diagnostic Accuracy of TCD for Brain Death: Systematic Review & Meta-Analysis. AJNR. 2016.
- Monteiro LM et al. TCD to confirm brain death: a meta-analysis. Intensive Care Med. 2006.
- Ducrocq X et al. WFN Consensus on CCA diagnosis using Doppler-sonography. J Neurol Sci. 1998.
- Segura T et al. Recommendations for TCD use in CCA as diagnostic support for brain death. Rev Neurosci. 2009.
- Sharma D et al. Clinical Experience with TCD as a Confirmatory Test for Brain Death. Neurocrit Care. 2011.
Disclaimer of Information & Content
The information provided on the NeuraSignal website is intended for educational and informational purposes only and should not be construed as medical advice, a diagnostic opinion, or a guarantee of clinical outcome. While NeuraSignal strives to present accurate and up-to-date information sourced from peer-reviewed literature and reputable clinical references, NeuraSignal makes no representations or warranties regarding the completeness, accuracy, reliability, or timeliness of any content presented herein. No individual, including patients currently under clinical evaluation, should rely on the information, tools, or resources available on this website for self-diagnosis, self-treatment, or as a substitute for professional medical consultation. Clinical decisions should always be made in partnership with a qualified healthcare provider. NeuraSignal expressly disclaims any liability arising from the use or interpretation of the content on this website.